Gary Pollack
Document Actions
2. Pollack, GM and Shen, DD. Dose-dependent pharmacokinetics of antipyrine in the rat. Res. Comm. Chem. Path. Pharmacol. 44:69-81, 1984.
3. Pollack, GM, Slaughter, RL, Buchanan, JF, and Shen, DD. High-performance liquid chromatographic procedure for the determination of di-(2-ethylhexyl)phthalate in human blood specimens: Problems of variable-extraction yield and the use of standard addition for calibration. J. Chromatogr. Biomed. Appl. 311:101-108, 1984.
4. Pollack, GM, Baswell, B, Szefler, SJ, and Shen, DD. Comparison of inter- and intra-subject variation in oral absorption of theophylline from sustained-release products. Int. J. Pharmaceut. 21:3-16, 1984.
5. Shen, DD and Pollack, GM. A reply to “Problems involved with developing a suitable model for evaluating exposure to bis(2-ethylhexyl)phthalate for medical devices. J. Pharm. Sci. 73:1334, 1984.
6. Pollack, GM and Shen, DD. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J. Pharmacol. Meth. 13:135-146, 1985.
7. Pollack, GM, Li, RCK, Ermer, JC, and Shen, DD. Effects of route of administration and repetitive dosing on the disposition kinetics of di-(2-ethylhexyl)phthalate and its mono-de-esterified metabolite in rats. Toxicol. Appl. Pharmacol. 79:246-256, 1985.
8. Pollack, GM, Buchanan, JF, Slaughter, RL, Kohli, RK, and Shen, DD. Circulating concentrations of di-(2-ethylhexyl)phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. Toxicol. Appl. Pharmacol. 79:257-267, 1985.
9. Pollack, GM, McHugh, WB, Gengo, FM, Ermer, JC, and Shen, DD. Accumulation and washout kinetics of valproic acid and its active metabolites. J. Clin. Pharmacol. 26:668-676, 1986.
10. Shrewsbury, RP, White, SG, Pollack, GM, and Wargin, WA. Antipyrine kinetics following partial blood exchange with Fluosol-DA in the rat. J. Pharm. Pharmacol. 38:883-887, 1986.
11. Tennison, MB, Miles, MV, Pollack, GM, Thorn, MD, and Dupuis, RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 29:543-547, 1988.
12. Pollack, GM, Shen, DD, and Dorr, MB. Contribution of metabolites to the route- and time-dependent hepatic effects of di-(2-ethylhexyl) phthalate in the rat. J. Pharmacol. Exp. Ther. 248:176-181, 1989.
13. Dorr, MB and Pollack, GM. Specific assay for the quantitation of indocyanine green in rat plasma using high performance liquid chromatography with fluorescence detection. J. Pharm. Sci. 78:328-333, 1989.
14. Pollack, GM, Brouwer, KLR, Demby, KB, and Jones, JA. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green and galactose. Drug Metab. Dispos. 18:197-202, 1990.
15. Liu, M-J, Scott, KR, and Pollack, GM. Pharmacokinetics and pharmacodynamics of valproic acid analogs in the rat. I. Spiro[4.6]undecane-2-carboxylic acid. Epilepsia 31:465-473, 1990.
16. Dupuis, RE, Lichtman, SN, and Pollack, GM. Acute valproic overdose: Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Safety 5:65-71, 1990.
17. Pollack, GM. Chromatographic analysis. Encyclopedia of Pharmaceutical Technology (J. Swarbrick and J.C. Boylan, eds.). Marcel Dekker, New York, 1990, pp. 419-445.
18. Pollack, GM and Brouwer, KLR. Effect of thermal injury on the disposition of indocyanine green in the rat: Hepatic blood flow and trans-hepatic extraction. Pharm. Res. 8:106-111, 1991.
19. Pollack, GM, Browne, JL, Marton, J, and Haberer, LJ. Chronic stress impairs oxidative metabolism and hepatic excretion of model xenobiotic substrates in the rat. Drug Metab. Dispos. 19:130-134, 1991.
20. Haberer, LJ and Pollack, GM. Central nervous system uptake kinetics of pentylenetetrazol in the developing rat. Biopharm. Drug Disp. 12:59-71, 1991.
21. Pollack, GM and Brouwer, KLR. Pharmacokinetic implications of enterohepatic recirculation: Simulation studies based upon the disposition of valproic acid in the rat. J. Pharmacokinet. Biopharm. 19:189-225, 1991.
22. Pollack, GM and Kawagoe, JL. Determination of methanol in whole blood by capillary gas chromatography with direct on-column injection. J. Chromatogr. Biomed. Appl. 570:406-411, 1991.
23. Horton, TL and Pollack, GM. Enterohepatic recirculation and renal metabolism of morphine in the rat. J. Pharm. Sci. 80:1147-1152, 1991.
24. Suttle, AB, Pollack, GM, and Brouwer, KLR. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res. 9:350-356, 1992.
25. Liu, M-J, Brouwer, KLR, and Pollack, GM. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat. Drug Metab. Dispos. 20:810-815, 1992.
26. Brouwer, KLR, Hall, ES, and Pollack, GM. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats. Biochem. Pharmacol. 45:735-742, 1993.
27. Liu, M-J and Pollack, GM. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Biopharm. Drug Dispos. 14:325-339, 1993.
28. Pollack, GM, Brouwer, KLR, and Kawagoe, JL. Toxicokinetics of intravenous methanol in the female rat. Fund. Appl. Toxicol. 21:105-110, 1993.
29. Golden, PL, Brouwer, KR, and Pollack, GM. Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis. Pharm. Res. 10:1765-1771, 1993.
30. Haberer, LJ and Pollack, GM. Disposition and protein binding of valproic acid in the developing rat. Drug Metab. Dispos. 22:113-119, 1994.
31. Pollack, GM, Brouwer, KLR, Spencer, AP, and Horton, TL. Gastrointestinal hydrolysis of valproate- and morphine glucuronide in the developing rat. Drug Metab. Dispos. 22:120-123, 1994.
32. Liu, M-J and Pollack, GM. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclo-hexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 35:234-243, 1994.
33. Cato A, Pollack, GM, and Brouwer, KLR. Age-dependent intestinal absorption of valproic acid in the rat. Pharm. Res. 12:284-290, 1995.
34. Ouellet, DM-C and Pollack, GM. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab. Dispos. 23:478-484, 1995.
35. Slattum, PW, Cato, AE, Pollack, GM, and Brouwer, KLR. Age-dependent intestinal hydrolysis of valproate glucuronide in the rat. Xenobiotica 25:229-237, 1995.
36. Ward, KW, Perkins, RA, Kawagoe, JL, and Pollack, GM. Comparative toxicokinetics of methanol in the female rat and mouse. Fund. Appl. Toxicol. 26:258-264, 1995.
37. Perkins, RA, Ward, KW, and Pollack, GM. A pharmacokinetic model of inhaled methanol in the human and comparison to disposition in the mouse and rat. Environ. Health Perspectives 103:726-733, 1995.
38. Perkins, RA, Ward, KW, and Pollack, GM. Comparative toxicokinetics of inhaled methanol in the female CD-1 mouse and Sprague-Dawley rat. Fund. Appl. Toxicol. 28:245-254, 1995.
39. Ouellet, DM-C and Pollack, GM. Kinetics of tolerance development to morphine analgesia. J. Pharmacokinet. Biopharm. 23:531-549, 1995.
40. Gaudreault, J, Varin, F, and Pollack, GM. Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL284,846, in rats. Pharm. Res. 12:1592-1597, 1995.
41. Booth, CL, Pollack, GM, and Brouwer, KLR. Hepatobiliary disposition of valproic acid and valproate glucuronide: Use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 23:771-780, 1996.
42. Chen, C, Slattum, PW, Brouwer, KLR, and Pollack, GM. Influence of age and gender on valproic acid glucuronidation in rats. Drug Metab. Dispos. 24:367-370, 1996.
43. Slattum PW, Cato A, Pollack GM, and Brouwer KLR. Age-related changes in valproic acid binding to rat serum proteins in vitro. J. Pharm. Sci. 85:373-376, 1996.
44. Perkins, RA, Ward, KW, and Pollack, GM. Methanol inhalation: Site and other factors influencing absorption and an inhalation toxicokinetic model for the rat. Pharm. Res. 13:749-755, 1996.
45. Carlton LD, Pollack, GM, and Brouwer, KLR. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: Implications for patients with congestive heart failure receiving epoprostenol. J. Pharm. Sci. 85:473-477, 1996.
46. Chen, C and Pollack, GM. Development of a capillary zone electrophoresis assay to examine the disposition of [D-Pen2,5]enkephalin in rats. J. Chromatogr. Biomed. Appl. 681:363-373, 1996.
47. Gaudreault, J, Varin, F, and Pollack, GM. Anticonvulsant pharmacodynamics and disposition of triazolam in rats. J. Pharm. Sci. 85:999-1004, 1996.
48. Matheny, CJ, Taft, DR, Brouwer, KLR, and Pollack, GM. Evidence for reversible sequestration of morphine in rat liver. Biochem. Pharmacol. 52:535-541, 1996.
49. Perkins, RA, Ward, KW, and Pollack, GM. Ventilation of ambulatory rats exposed to methanol vapor in a flow-through exposure system: Measurement and input to toxicokinetic models. Inhal. Toxicol. 8:143-162, 1996.
50. Ward, KW and Pollack, GM. Use of intrauterine microdialysis to investigate methanol-induced alterations in uteroplacental blood flow. Toxicol. Appl. Pharmacol. 140:203-210, 1996.
51. Ward, KW and Pollack, GM. Comparative toxicokinetics of methanol in pregnant and nonpregnant rodents. Drug Metab. Dispos. 24:1062-1070, 1996.
52. Lin, P-H, Waidyanatha, S., Pollack, GM, and Rappaport, SM. Dosimetry of chlorinated quinone metabolites of pentachlorophenol in the livers of rats and mice based upon measurement of protein adducts. Toxicol. Appl. Pharmacol. 145:399-408, 1997.
53. Liu, X, Pollack, GM, and Brouwer, KLR. A modified residual method to estimate the zero-order absorption rate constant in a one-compartment model. Biopharm. Drug Dispos. 18:93-101, 1997.
54. Ouellet, DM-C and Pollack, GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem. Pharmacol. 53:1451-1457, 1997.
55. Ouellet, DM-C and Pollack, GM. Pharmacodynamics and tolerance development during multiple iv bolus morphine administration in rats. J. Pharmacol. Exp. Ther. 281:713-720, 1997.
56. Ward, KW, Blumenthal, GM, Welsch, F, and Pollack, GM. Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice. Toxicol. Appl. Pharmacol. 145:311-322, 1997.
57. Nolting, A, DeLong, RK, Fisher, MH, Wickstrom, E, Pollack, GM, Juliano, RL, and Brouwer, KLR. Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver. Pharm. Res. 14:516-521, 1997.
58. Chen, C and Pollack, GM. Extensive biliary excretion of the model opioid peptide [D-PEN2,5]enkephalin in rats. Pharm. Res. 14:345-350, 1997.
59. Chen, C, Jeffery, D, Jorgenson, JW, Moseley, MA, and Pollack, GM. Sensitive analysis of [D-Pen2,5]enkephalin in rat serum by capillary electrophoresis and laser-induced fluorescence detection. J. Chromatogr. B. 697:149-162, 1997.
60. Chen, C and Pollack, GM. Blood-brain disposition and antinociceptive effects of [D-penicillamine2,5]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 283:1151-1159, 1997.
61. Troy, SM, Parker, VP, Hicks, DR, Pollack, GM, and Chiang, ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J. Clin. Pharmacol. 37:954-961, 1997.
62. Rittenhouse, KD, Peiffer, RL, and Pollack, GM. Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. J. Pharmaceut. Biomed. Anal. 16:951-959, 1998.
63. Golden, PL and Pollack, GM. Rationale for influx enhancement versus efflux blockade to increase drug exposure to the central nervous system. Biopharm. Drug Dispos. 19:263-272, 1998.
64. Letrent, SP, Pollack, GM, Brouwer, KR, and Brouwer, KLR. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:599-605, 1998.
65. Chen C and Pollack GM. Altered disposition and antinociception of [D-Penicillam-ine2,5]enkephalin in mdr1a-gene-deficient mice. J. Pharmacol. Exp. Ther. 287:545-552, 1998.
66. Schroeder TJ, Cho MJ, Pollack GM, Floc'h R, Moran HB, Levy R, Moore LW, and Pouletty P. Comparison of two cyclosporine formulations in healthy volunteers: Bioequivalence of the new Sang-35 formulation and Neoral. J. Clin. Pharmacol.. 38:807-814, 1998.
67. Chen, C and Pollack, GM. Enhanced antinociception of the model opioid peptide [D-penicillamine2,5]enkephalin by P-glycoprotein modulation. Pharm. Res. 16:296-301, 1999.
68. Letrent, SP, Pollack, GM, Brouwer, KR, and Brouwer, KLR. Effects of GF120918 on blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27:827-834, 1999.
69. Lin, P-H, Waidyanatha, S, Pollack, GM, Swenberg JA, and Rappaport, SM. Dose-specific production of chlorinated quinine and semiquinone adducts in rodent livers following administration of pentachlorophenol. Toxicol. Sci. 47:126-133, 1999.
70. Rittenhouse, KD, Peiffer, RL, and Pollack, GM. Microdialysis evaluation of the ocular pharmacokinetics of propranolol in the conscious rabbit. Pharm. Res. 16:736-742, 1999.
71. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, and Brouwer KLR. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 58:951-957, 1999.
72. Rittenhouse, KD, Peiffer, RL, and Pollack GM. Assessment of ascorbate ocular disposition in the conscious rabbit: an approach using the microdialysis technique. Curr. Eye Res. 20:351-360, 2000.
73. Rittenhouse, KD and Pollack, GM. Pharmacodynamics of beta-blocker modulation of aqueous humor production. Exp. Eye Res. 70:429-439, 2000.
74. Dagenais, C, Rousselle, C, Pollack, GM, and Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cerebral Blood Flow Metab. 20:381-386, 2000.
75. Aquilante, CL, Letrent, SP, Pollack, GM, and Brouwer KLR. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66:PL47-51, 2000.
76. Zong, J and Pollack, GM. Modulation of morphine antinociception by P-glycoprotein activity and expression in mice. Pharm. Res. 17:749-753, 2000.
77. Ward, ES, Pollack, GM, and Brouwer, KLR. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: Can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? Drug Metab. Dispos. 28:1433-1439, 2000.
78. Rittenhouse, KD and Pollack, GM. Microdialysis and drug delivery to the eye. Adv. Drug Del. Rev. 45:229-241, 2000.
79. Bush, MA and Pollack, GM. Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazole. Biopharm. Drug Dispos. 21:221-228, 2000.
80. Dagenais, C, Ducharme, J, and Pollack, GM. Uptake and efflux of the peptidic delta-opioid receptor agonist [D-penicillamine2,5]-enkephalin at the murine blood-brain barrier by in situ perfusion. Neurosci. Letters 301:155-158, 2001.
81. Ward, ES, Pollack, GM, and Brouwer, KLR. Probenecid-associated alterations in Valproate glucuronide hepatobiliary disposition: Mechanistic assessment utilizing mathematical modeling. J. Pharmacol. Exp. Ther. 297:141-147, 2001.
82. Bush, MA and Pollack, GM. Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus. Pharm. Res. 18:1607-1612, 2001.
83. Arens, TL and Pollack, GM. Nonstationary disposition of valproic acid during prolonged intravenous infusion: Contributions of unbound clearance and protein binding. Biopharm. Drug Dispos. 22:243-249, 2001.
84. Dagenais, C, Zong, J, Ducharme, J, and Pollack, GM. Effect of mdr1a P-glycoprotein gene disruption, gender, and concentration on the brain uptake of substrates. Pharm. Res. 18:957-963, 2001.
85. Matheny, CJ, Lamb, MW, Brouwer, KLR, and Pollack, GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 21:778-796, 2001.
86. Yeleswaram, S, Pollack, GM, Brouwer, KLR, and Ward, ES. Probenecid-Associated Alterations in Valproic Acid Pharmacokinetics in Rats: Can in Vivo Disposition of Valproate Glucuronide Be Predicted from in Vitro Formation Data? Drug Metab. Dispos. 29: 777, 2001.
87. Dagenais C. Ducharme J. Pollack GM. Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy. J. Pharm. Sci. 91:244-252, 2002.
88. Murthy, BP, Pollack, GM, and Brouwer, KLR. Contribution of morphine-6-glucuronide to to antinociception following intravenous administration of morphine to healthy volunteers. J. Clin. Pharmacol. 42:569-576, 2002.
89. Xiong, H, Suzuki, H, Sugiyama, Y, Meier, PJ, Pollack, GM, and Brouwer, KLR. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab. Dispos. 30:962-9699, 2002.
90. Heinzen, EL and Pollack, GM. Use of an electrochemical nitric oxide sensor to detect neuronal nitric oxide production in conscious, unrestrained rats. J. Pharmacol. Toxicol. Meth. 48:139-146, 2002.
91. Brouwer, KLR and Pollack, GM. Pharmacogenetics: is the right drug for the right patient sufficient? Adv. Drug Deliv. Rev. 54:1243-1244, 2002.
92. Zamek-Gliszczynski, MJ, Xiong, H, Patel, NJ, Turncliff, RZ, Pollack, GM and Brouwer, KLR. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. J. Pharmacol. Exp. Ther. 304: 801-809, 2003.
93. Golden, PL and Pollack, GM. Blood-brain barrier efflux transport. J. Pharm. Sci. 92:1739-1753, 2003.
94. Graff, CL and Pollack, GM. P-glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm. Res. 20:1225-1230, 2003.
95. Zong, J and Pollack, GM. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J. Pharmacol. Exp. Ther. 306:556-562, 2003.
96. Heinzen, EL and Pollack, GM. Pharmacokinetics and pharmacodynamics of L-arginine in rats: A model of stimulated neuronal nitric oxide synthesis. Brain Res. 989:67-75, 2003.
97. Graff, CL and Pollack, GM. Drug transport at the blood-brain barrier and the choroids plexus. Curr. Drug Metab. 5:95-108, 2004.
98. Persky, AM, Berry, NS, Pollack, GM, and Brouwer KLR. Modelling the cardiovascular effects of ephedrine. Br. J. Clin. Pharmacol. 57:552-562, 2004.
99. Heinzen, EL and Pollack, GM. The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. Biochem. Pharmacol. 67:735-741, 2004.
100. Dagenais C, Graff CL, and Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67:269-276, 2004.
101. Kalvass, JC, Graff, CL and Pollack, GM. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharm. Res. 21:1867-1870, 2004.
102. Matheny, CJ Ali, RY, Yang, X, and Pollack, GM. Effect of prototypical inducing agents on P-glycoprotein and cytochrome P450 3A expression in mouse tissues. Drug Metab. Dispos. 32:1008-1014, 2004.
103. Persky, AM, Berry, NS, Pollack, GM, and Brouwer, KLR. Modelling the cardiovascular effects of ephedrine. Br. J. Clin. Pharmacol. 57:552-562, 2004.
104. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KLR. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther. 311:1203-1210, 2004.
105. Heinzen, EL and Pollack, GM. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Res. 15:175-184, 2004.
106. Graff, CL and Pollack, GM. Influence of P-glycoprotein on brain uptake: Comparison of nasal administration to in situ brain perfusion. J. Pharm. Sci 94:1187-1195, 2005.
107. Heinzen, EL, Booth, RG, and Pollack, GM. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor. Biochem. Pharmacol. 69:679-688, 2005.
108. Hoffmaster, KA, Zamek-Gliszczynski, MJ, Pollack, GM, and Brouwer, KLR. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab. Dispos. 33:287-293, 2005.
109. Graff, CL and Pollack, GM. Functional evidence for P-glycoprotein at the nose-brain interface. Pharm. Res. 22:86-93, 2005.
110. Graff, CL, Zhao, R, and Pollack, GM. Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation. Pharm. Res. 22: 235-244, 2005.
111. Graff, CL and Pollack, GM. Nasal drug administration: Potential for targeted central nervous system delivery. J. Pharm. Sci. 94:1187-1195, 2005.
112. Chandra P, Johnson BM, Zhang P, Pollack GM, and Brouwer KLR. Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab Dispos. 33:1238-1243, 2005.
113. Bourdet, DL, Pollack, GM, and Thakker, DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res. 23:1178-1187, 2006.
114. Turncliff, RZ, Hoffmaster, KA, Kalvass, JC, Pollack, GM, and Brouwer KLR. Hepatobiliary disposition of a drug-metabolite pair: Comprehensive pharmacokinetic modeling in sandwich cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 318:881-889, 2006.
115. Bauer, B, Yang, X, Hartz, AM, Olson, ER, Zhao, R, Kalvass, JC, Pollack, GM, and Miller, DS. In vivo activation of human PXR tightens the blood-brain barrier to methadone through P-glycoprotein upregulation. Mol. Pharmacol. 70:1212-1219, 2006.
116. Kalvass, JC and Pollack, GM. Kinetic Considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24:265-276, 2007.
117. Kalvass, JC, Maurer, TS, and Pollack, GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of thirty-four drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab. Dispos. (in press).
118. Kalvass, JC, Olson, ER, and Pollack, GM. Influence of blood-brain barrier P-glycoprotein on brain penetration and antinociceptive effects of model opioids. Drug Metab. Dispos. (in press).
119. Kalvass, JC, Olson, ER, and Pollack, GM. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab. Dispos. (in press).
120. Kalvass, JC, Olson, ER, and Pollack, GM. Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-gp-Competent Mice: Assessment of Unbound Brain EC50 and Correlation of In Vitro, Preclinical, and Clinical Data. J. Pharmacol. Exp. Ther. (in review).
121. Graff, CL and Pollack, GM. Targeted blood-brain barrier P-glycoprotein inhibition via nasal delivery. Pharm. Res. (in preparation).
122. Kalvass, JC, Maurer, TS, and Pollack, GM. Clinical inhibition of P-glycoprotein at the blood-brain barrier: A pharmacokinetic-pharmacodynamic assessment. Clin. Pharmacol. Ther. (in preparation).
Abstracts
1. Shen, DD, Pollack, GM, Cohen, ME, Duffner, P, Lacey, D, and Ryan-Dudek, P. Effect of age on the serum metabolite pattern of valproic acid in epileptic children. Epilepsia 25:674, 1984.
2. Dorr, MB and Pollack, GM. Induction of antipyrine metabolism by di-(2-ethylhexyl) phthalate and 2-ethylhexanol. Abstracts, APhA Academy of Pharmaceutical Sciences, 15:111, 1985.
3. Shrewsbury, RP, Dorr, MB, and Pollack, GM. Effects of anesthesia and blood replacement on antipyrine kinetics in rats. Abstracts, APhA Academy of Pharmaceutical Sciences, 15:111, 1985.
4. Dorr, MB, Weigel, SJ, and Pollack, GM. The effect of thermal injury on antipyrine disposition in rats. Abstracts, APhA Academy of Pharmaceutical Sciences, 15:147, 1985.
5. Dorr, MB, Weigel, SJ, and Pollack, GM. Alterations in hepatic blood flow following thermal injury in the rat. Abstracts, APhA Academy of Pharmaceutical Sciences, 15:147, 1985.
6. Haberer, LJ, Weigel, SJ, and Pollack, GM. Gender-based differences in the hepatic response to thermal injury. Abstracts, APhA Academy of Pharmaceutical Sciences, 15:148, 1985.
7. Liu, M-J, Scott, KR, and Pollack, GM. Unusual nonlinearity in the disposition of spiro [4.6] undecane carboxylic acid in rats. Pharm. Res. 3:147S, 1986.
8. Dorr, MB and Pollack, GM. The protective effect of fluid resuscitation on thermal injury-induced inhibition of antipyrine metabolism in rats. Pharm. Res. 3:147S, 1986.
9. Haberer, LJ and Pollack, GM. The disposition of a subconvulsant dose of pentylenetetrazol in rats. Pharm. Res. 3:145S, 1986.
10. Horton, TL and Pollack, GM. A rapid and sensitive assay for investigations of haloperidol disposition in rodents. Pharm. Res. 3:145S, 1986.
11. Longstreth, J and Pollack, GM. Numerical estimation of the fraction of a dose subjected to enterohepatic circulation. Pharm. Res. 3:115S, 1986.
12. Pollack, GM. Pharmacokinetic factors contributing to the nonlinear disposition of valproic acid in the rat. Pharm. Res. 3:145S, 1986.
13. Demby, KB, Pollack, GM, and Longstreth, JA. Determination of trimethoprim in the blood and selected tissues of the rat by RP-HPLC and UV detection. Pharm. Res. 3:129S, 1986.
14. Tennison, MB, Miles, MV, Pollack, GM, and Dupuis, RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 28:627, 1987.
15. Dorr, MB and Pollack, GM. The effect of thermal injury on the metabolic profile of antipyrine in the rat. Japanese-United States Congress of Pharmaceutical Sciences, 1987.
16. Haberer, LJ and Pollack, GM. Developmental changes in the pharmacodynamics of valproic acid. Japanese-United States Congress of Pharmaceutical Sciences, 1987.
17. Pollack, GM and Brouwer, KLR. Dose-dependent metabolism and biliary excretion of valproic acid and valproate glucuronide in the rat. Pharm. Res. 5:S-163, 1988.
18. Brouwer, KLR, Durham, S, Jones, J, Pollack, GM, and Vore, M. Estradiol-17ß(ß-D-glucuronide) induced cholestasis: Experimental model for studying altered indocyanine green disposition. Pharm. Res. 5:S-195, 1988.
19. Haberer, LJ and Pollack, GM. Computer-based convulsion meter for anticonvulsant studies in the developing rat. Pharm. Res. 5:S-226, 1988.
20. Liu, MJ, Haberer, LJ, and Pollack, GM. Application of statistical moment analysis under nonlinear conditions. Pharm. Res. 5:S-226, 1988.
21. Horton, TL and Pollack, GM. A sensitive and specific HPLC assay for determination of morphine in rat serum. Pharm. Res. 5:S-228, 1988.
22. Haberer, LJ and Pollack, GM. Pharmacokinetics of valproic acid in developing rats. Pharm. Res. 6:S-186, 1989.
23. Liu, MJ and Pollack, GM. Pharmacokinetics and pharmacodynamics of cyclohexane-carboxylic acid. Pharm. Res. 6:S-187, 1989.
24. Pollack, GM and Brouwer, KLR. Kinetics of enterohepatic recirculation: Simulations based upon the disposition of valproic acid in the rat. Pharm. Res. 6:S-187, 1989.
25. Demby, KB and Pollack, GM. Toxicodynamics of phthalate ester plasticizers: Structure-activity influences on oxidative metabolism. Pharm. Res. 6:S-202, 1989.
26. Horton, TL and Pollack, GM. Investigation of renal metabolism and enterohepatic recirculation of morphine in the rat. Pharm. Res. 6:S-203, 1989.
27. Pollack, GM and Brouwer, KLR. Sequential infusion of indocyanine green or galactose to estimate hepatic blood flow in the rat. Pharm. Res. 6:S-210, 1989.
28. Demby, KB and Pollack, GM. Toxicodynamics of phthalate ester plasticizers II: Structure-activity influences of alcohol metabolites on oxidative metabolism. Pharm. Res. 7:S-220, 1990.
29. Liu, MJ and Pollack, GM. Pharmacokinetics and pharmacodynamics of 1-methyl-1-cyclohexanecarboxylic acid. Pharm. Res. 7:S-233, 1990.
30. Suttle, AB, Pollack, GM, and Brouwer, KLR. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res. 7:S-260, 1990.
31. Murphy, K and Pollack, GM. The effect of hyperglycemia induced by glucose infusion on antipyrine metabolism in the rat. Pharm. Res. 7:S-265, 1990.
32. Brouwer, KLR and Pollack, GM. Protein binding and hepatobiliary distribution of valproate and VPA glucuronide in rats. Pharm. Res. 7:S-279, 1990.
33. Ouellet, DM-C and Pollack, GM. Development of tolerance to the analgesic effect of morphine. Pharm. Res. 8:S-247, 1991.
34. Johnson, L, Pollack, GM, and Brouwer, KLR. Effect of phenobarbital on the disposi¬tion of valproic acid in the isolated perfused rat liver. Pharm. Res. 8:S-259, 1991.
35. Cato, A, Pollack, GM, and Brouwer, KLR. Intestinal absorption of valproic acid in the developing rat. Pharm. Res. 8:S-259, 1991.
36. Spencer, AP, Horton, TL, Brouwer, KLR, and Pollack, GM. Age-dependent gastroin-testinal hydrolysis of valproate- and morphine-glucuronide. Pharm. Res. 8:S-282, 1991.
37. Horton, TL, Brouwer, KLR, and Pollack, GM. Morphine kinetics in the aging rat. Pharm. Res. 8:S-282, 1991.
38. Liu, M-J, Brouwer, KLR, and Pollack, GM. Biliary excretion and choleretic effect of valproic acid analogs. Pharm. Res. 8:S-282, 1991.
39. Kawagoe, JL, Brouwer, KLR, and Pollack, GM. Pharmacokinetics of intravenous methanol in the rat. Pharm. Res. 8:S-282, 1991.
40. Golden, PL, Brouwer, KR, and Pollack, GM. Assessment of valproic acid serum-CSF transport kinetics by microdialysis. Pharm. Res. 8:S-247, 1991.
41. Haberer, LJ and Pollack, GM. Blood-brain transport kinetics of valproic acid in the developing rat. Pharm. Res. 8:S-322, 1991.
42. Jewell, RC, Chiou, Y-J, and Pollack, GM. Influence of valproic acid glucuronide on protein binding of valproic acid. Pharm. Res. 9:S-337, 1992.
43. Kawagoe, JL, Brouwer, KLR, and Pollack, GM. Parallel linear and nonlinear elimination of methanol in the rat. Pharm. Res. 9:S-271, 1992.
44. Golden, PL and Pollack, GM. Theoretical advantages of uptake enhancement over efflux blockade to increase central nervous system drug exposure. Pharm. Res. 9:S-349, 1992.
45. Atwa, N, Maguire, JH, and Pollack, GM. 5-Alkyl-5-phenylhydantoins: Structure-pharmacokinetic relationships. Pharm. Res. 9:S-271, 1992.
46. Ouellet, DM-C and Pollack, GM. Pharmacodynamics of morphine during infusion in rats. Pharm. Res. 9:S-266, 1992.
47. Gaudreault, J, Varin, F, and Pollack, GM. Pharmacodynamics of triazolam: Anticonvulsant action and tolerance development. Pharm. Res. 9:S-358, 1992.
48. Horton, TL, Brouwer, KLR, and Pollack, GM. Morphine metabolism in the aging rat. Pharm. Res. 9:S-290, 1992.
49. Cato, A, Minecci, L, Pollack, GM, and Brouwer, KLR. Age-dependent disposition of valproic acid in the rat. Pharm. Res. 9:S-267, 1992.
50. Cato, A, Pollack, GM, and Brouwer, KLR. Age-dependent alterations in the extent and mechanism of valproic acid intestinal absorption in the rat. Pharm. Res. 9:S-347, 1992.
51. Ouellet, DM-C and Pollack, GM. Morphine and morphine-3-glucuronide pharmaco-kinetics in intact and bile duct cannulated rats. Pharm. Res. 10:S-3, 1993.
52. Ouellet, DM-C and Pollack, GM. Morphine pharmacodynamics with and without prior exposure to morphine-3-glucuronide. Pharm. Res. 10:S-361, 1993.
53. Horton, TL, Brouwer, KLR, and Pollack, GM. Age-dependent morphine disposition in the isolated perfused rat liver. Pharm. Res. 10:S-369, 1993.
54. Pollack, GM. A kinetic model for systemic elimination limited by receptor binding: Application to morphine. Pharm. Res. 10:S-380, 1993.
55. Gaudreault, J, Varin, F, and Pollack, GM. Pharmacokinetics and pharmacodynamics of CL284,846 in rats. Pharm. Res. 10:S-386, 1993.
56. Cato, A, Slattum, PW, Pollack, GM, and Brouwer, KLR. Effects of age and gender on valproate disposition in the bile duct cannulated rat. Pharm. Res. 10:S-392, 1993.
57. Slattum, PW, Cato, A, Pollack, GM, and Brouwer, KLR. Age-related changes in valproic acid binding to rat serum proteins in vitro. Pharm. Res. 10:S-392, 1993.
58. Golden, PL and Pollack, GM. Effect of valproic acid on the systemic disposition of zidovudine in the rat. Pharm. Res. 10:S-392, 1993.
59. Suttle, AB, Pollack, GM, and Brouwer, KLR. Intestinal secretion of ranitidine from in situ rat intestine. Pharm. Res. 10:S-413, 1993.
60. Golden, PL. Patel, SR, and Pollack, GM. Effect of valproic acid on CNS disposition of zidovudine in the rat. Pharm. Res. 11:S-333, 1994.
61. Ouellet, DM-C and Pollack, GM. A PK-PD model of tolerance to morphine analgesia. Pharm. Res. 11:S-334, 1994.
62. Chen, C, Slattum, PW, Brouwer, KLR, and Pollack, GM. Influence of gender on the glucuronidation of valproic acid in senescent rats. Pharm. Res. 11:S-383, 1994.
63. Taft, DR, Matheny, CJ, Brouwer, KLR, and Pollack, GM. Evidence for reversible binding of morphine in the isolated perfused rat liver. Pharm. Res. 11:S-388, 1994.
64. Carlton, LD, Pollack, GM, and Brouwer, KLR. Effect of gastrointestinal blood flow on absorption: Implications for patients receiving epoprostenol. Pharm. Res. 11:S-416, 1994.
65. Booth, CL, Pollack, GM, and Brouwer, KLR. Development of a kinetic model to examine perturbations in the hepatobiliary disposition of valproic acid (VPA) and VPA glucuronide. Pharm. Res. 11:S-418, 1994.
66. Liu, X, Pollack, GM, and Brouwer, KLR. A new residual method to estimate the zero-order absorption rate constant in a one-compartment model. Pharm. Res. 11:S-418, 1994.
67. Gaudreault, J, Varin, F, and Pollack, GM. Tolerance to the hypnotic effect of triazolam in rats. Pharm. Res. 11:S-423, 1994.
68. Golden, PL and Pollack, GM. Central nervous system (CNS) transport kinetics and uptake enhancement of zidovudine (AZT) in rats. Pharm. Res. 12:S-3, 1995.
69. Chen C and Pollack, GM. Use of capillary zone electrophoresis (CZE) to examine the pharmacokinetics of an opioid peptide in rats. Pharm. Res. 12:S-335, 1995.
70. Cato A, Pollack, GM, and Brouwer, KLR. Development of pharmacokinetic models to examine age-dependent elimination and enterohepatic recirculation of valproic acid (VPA) in the rat. Pharm. Res. 12:S-357, 1995.
71. Bush MA and Pollack, GM. The nitric oxide synthase inhibitor NG-nitro-L-arginine (NO2-ARG) attenuates tolerance to morphine (MOR) antinociception in the rat. Pharm. Res. 12:S-405, 1995.
72. Ward, KW and Pollack, GM. Maternal-fetal toxicokinetics of methanol. The Toxicologist 15:995, 1995.
73. Letrent, SP, Pollack, GM, Brouwer, KB, and Brouwer, KLR. Effect of GW918, a potent p-glycoprotein inhibitor, on morphine pharmacokinetics (PK) and pharmacodynamics (PD) in the rat. Pharm. Res. 13:S-604, 1996.
74. Rittenhouse, KD and Pollack, GM. Ocular absorption of propranolol: Development of an in vivo model with microdialysis (MD) sampling of aqueous humor. Pharm. Res. 13:S-604, 1996.
75. Bush, MA and Pollack, GM. Morphine (MOR) tolerant rats display enhanced brain nitric oxide synthase (bNOS) activity. Pharm. Res. 13:S-604, 1996.
76. Moore, KHP and Pollack, GM. Evaluation of logistic and sigmoid Emax methods for modeling concentration (C) vs. effect (E) data. Pharm. Res. 13:S-604, 1996.
77. Chen, C and Pollack, GM. In Vivo disposition and biliary excretion of a model opioid peptide in rats. Pharm. Res. 13:S-604, 1996.
78. Nolting, A, DeLong, RK, Fisher, M, Wickstrom, E, Juliano, RL, Pollack, GM, and Brouwer, KLR. Hepatic distribution and clearance of antisense oligonucleotides. Pharm. Res. 13:S-604, 1996.
79. Ward, ES, Pollack, GM, and Brouwer, KLR. Effect of probenecid on valproic acid steady-state disposition in rats. The Toxicologist 30:36(189), 1996.
80. Ward, KW, Blumenthal, GM, Welsch, F, and Pollack, GM. Development of a physiologically based pharmacokinetic model for methanol in pregnant rats and mice. The Toxicologist 30:1273, 1996.
81. Ward, KW, Blumenthal, GM, Welsch, F, and Pollack, GM. Toxicokinetics of methanol in the pregnant rat and mouse: Development of a physiologically based pharmacokinetic model. The Toxicologist 49:353, 1996.
82. Nolting, A, Pollack, GM, Juliano, RL, and Brouwer, KLR. Distribution of a phosphorothioate antisense oligonucleotide in the presence and absence of uptake-enhancing agents in the isolated perfused rat liver. Pharm. Res. 14:S-738, 1997.
83. Chen, C and Pollack, GM. Blood-brain disposition and antinociception of the model opioid peptide [D-PEN2,5]enkephalin (DPDPE): Modulation by p-glycoprotein (P-GP). Pharm. Res. 14:S-738, 1997.
84. Bush, MA, Schmith, VD, and Pollack, GM. Determination of optimum sampling-regimen design to estimate pharmacokinetic parameters for a rapidly eliminated xenobiotic. Pharm. Res. 14:S-738, 1997.
85. Chen, C and Pollack, GM. GW918, a p-glycoprotein modulator, significantly enhances antinociception of the model opioid peptide [D-PEN2,5]enkephalin (DPDPE) in mice. Pharm. Res. 14:S-738, 1997.
86. Dagenais, C, Koch, AM, Suttle, AB, and Pollack, GM. Evaluation of a charcoal adsorption method for determination of drug protein binding. Pharm. Res. 14:S-738, 1997.
87. Elliott, TL and Pollack, GM. Lack of modulation of valproate anticonvulsant activity by administration kinetics in a rat model of epilepsy. Pharm. Res. 14:S-738, 1997.
88. Letrent, SP, Polli, JW, Humphreys, JE, Witherspoon, SM, Brouwer, KR, Pollack, GM, and Brouwer, KLR. Evaluation of the effect of p-glycoprotein inhibitors on the cellular accumulation of morphine in two blood-brain barrier cell types. Pharm. Res. 14:S-738, 1997.
89. Dagenais, C, Meachem, F, and Pollack, GM. Influence of (+)verapamil on CNS opioid disposition. PharmSci 1:S-600, 1998.
90. Zong, J and Pollack, GM. Effects of putative CNS efflux transporters on drug distribution and elimination PharmSci 1:S-237, 1998.
91. Zong, J and Pollack, GM. Morphine antinociception is enhanced in mdr1a gene-knockout mice. PharmSci 1:S-396, 1998.
92. Aquilante, CL, Letrent, SP, Pollack, GM and Brouwer, KLR: Increased brain P-glycoprotein expression in morphine tolerant rats. PharmSci 1:S-396, 1998.
93. Ng, C, Brouwer, KLR, and Pollack, GM. Use of pharmacokinetic models to examine the influence of opioid lipophilicity and CSF flow on the disposition of intrathecal opioids. Pharm. Res. PharmSci 1:S-678, 1998.
94. Rittenhouse, KD and Pollack, GM. Development of a conscious rabbit microdialysis model for evaluating the ocular disposition of a beta-adrenergic antagonist. PharmSci 1:S-567, 1998.
95. Bush, MA and Pollack, GM. Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazol. PharmSci 1:S-66, 1998.
96. Letrent, SP, Pollack, GM, Polli, JW, Brouwer, KR, and Brouwer, KLR. P-glycoprotein-mediated transport of morphine in the central nervous system. PharmSci 1:S-391, 1998.
97. Zong, J and Pollack, GM. A novel capillary zone electrophoresis assay for nicotine in biologic samples. PharmSci 1:www.aaps.org, 1999.
98. Dagenais, C, Rousselle C, Pollack, GM, and Scherrmann JM. Development of an in situ mouse brain perfusion model and its application in mdr1a P-glycoprotein-deficient animals. PharmSci 1:www.aaps.org, 1999.
99. Dagenais, C, Vranderick, M, Pollack, GM, and Boschi, G. Direct and sensitive analysis of the peptidic delta opioid agonist [D-pen2,5]-enkephalin (DPDPE) in mouse brain microdialysate by LC/MS/MS. PharmSci 1:www.aaps.org, 1999.
100. Bush, MA and Pollack, GM. Dynamics of nitric oxide as a mediator of morphine tolerance. PharmSci 1:www.aaps.org, 1999.
101. Booth, CL, Amos, P, Turncliff, R, LeCluyse, EL, Pollack, GM, and Brouwer, KLR. P-glycoprotein in sandwich-cultured rat hepatocytes is affected by culture time and inducers. PharmSci 1:www.aaps.org, 1999.
102. Matheny, CJ and Pollack, GM. Uptake of [D-pen2,5]-enkephalin (DPDPE) in mouse brain tissue slices: Effects of delta opioid receptor inhibition and P-glycoprotein expression. PharmSci 1:www.aaps.org, 1999.
103. Ward, ES, Pollack, GM, and Brouwer, KLR. Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: Mechanistic assessment utilizing mathematical modeling. PharmSci 3:www.aaps.org, 2000.
104. Dagenais, C, Ducharme, J, and Pollack, GM. Interaction of opioids and selected substrates with mdr1a P-glycoprotein in the blood-brain barrier. PharmSci 3:www.aaps.org, 2000.
105. Zong, J, Dagenais, C, Hall, JE, Allen, JL, and Pollack, GM. Brain uptake of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan and its prodrug by in situ mouse brain perfusion. PharmSci 3:www.aaps.org, 2000.
106. Murthy, BP, Radomski, KM, Brouwer, KLR, and Pollack, GM. Contribution of morphine-6-glucuronide (M6G) to analgesia following intravenous morphine administration in healthy volunteers. PharmSci 3:www.aaps.org, 2000.
107. Beaver, JLS and Pollack, GM. Optimization of a packed-bed charcoal-adsorption cartridge for assessing xenobiotic binding to human serum albumin. PharmSci 3:www.aaps.org, 2000.
108. Dagenais, C, Ducharme, J, and Pollack, GM. Effect of mdr1a P-glycoprotein (Pgp) genotype, gender, and substrate concentration on the brain uptake of Pgp substrates. PharmSci 3:www.aaps.org, 2000.
109. Matheny, CJ and Pollack, GM. Rifampin-associated induction of P-glycoprotein expression in rat leukocytes. PharmSci 3:www.aaps.org, 2000.
110. Chandra, P, Pollack, GM and Brouwer, KLR: Effects of taurocholate on fexofenadine biliary excretion: Influence of rate-limiting processes on hepatobiliary disposition. Hepatology 32:In press, 2000.
111. Graff, C, Allen, JL, Hall, JE, and Pollack, GM. Brain delivery of a novel orally active produg of the antiparasitic agent 2,5-bis(4-amidinophenyl)furan. PharmSci 3:www.aaps.org, 2001.
112. Zong, J and Pollack, GM. Effect of Flow Rate on P-glycoprotein Mediated Efflux in the Blood-Brain Barrier. PharmSci 3:www.aaps.org, 2001.
113. Matheny, CJ, Zong, J, Zhang, P, Phillips, B, Shen, DD, and Pollack, GM. Oxycodone Brain Uptake Following P-glycoprotein (P-gp) Induction by Morphine. PharmSci 3:www.aaps.org, 2001.
114. Dagenais, C, Ducharme, J, and Pollack, GM. Interaction of Nonpeptidic Delta Agonistswith P-glycoprotein by In Situ Mouse Brain Perfusion:LC-MS Analysis and Internal Standard Strategy. PharmSci 3:www.aaps.org, 2001.
115. Matheny, CJ, Ali, R and Pollack, GM. P-glycoprotein expression in mouse brain following chronic opioid treatment. AAPS PharmSci Vol. 4, No. 4, Abstract W4261, 2002.
116. Heinzen, EL and Pollack, GM. Pharmacokinetics and pharmacodynamics of L-arginine in rats: A model of stimulated neuronal nitric oxide synthesis. AAPS PharmSci Vol. 4, No. 4, Abstract W4225, 2002.
117. Zong, J, Cooper, N, and Pollack, GM. Modulation of P-glycoprotein transport activity in the murine blood-brain barrier by rifampin. AAPS PharmSci Vol. 4, No. 4, Abstract W4267, 2002.
118. Zong, J and Pollack, GM. The interplay between passive membrane permeability and P-glycoprotein affinity determines efflux transport at the blood-brain barrier. AAPS PharmSci Vol. 4, No. 4, Abstract W4287, 2002.
119. Graff, CL and Pollack, GM. P-glycoprotein-mediated exclusion of brain tissue uptake after intranasal administration. AAPS PharmSci Vol. 4, No. 4, Abstract W4260, 2002.
120. Yang, X and Pollack, GM. Quantitative analysis of rifampin for evaluating pharmacokinetics and tissue distribution in mice. AAPS PharmSci Vol. 5, No. 4, Abstract W5264, 2003.
121. Graff, CL and Pollack, GM. Evidence for two independent P-glycoprotein transport sites for quinidine at the murine blood-brain barrier. AAPS PharmSci Vol. 5, No. 4, Abstract W4382, 2003.
122. Kalvass, JC and Pollack, GM. Saturable brain uptake and P-glycoprotein-mediated efflux limit central nervous system exposure and antinociception of loperamide in mice. AAPS PharmSci Vol. 5, No. 4, Abstract W4381, 2003.
123. Matheny, C, Ali, RY, Yang, X, and Pollack, GM. Complex interaction of rifampin and digoxin: Evidence for concomitant P-glycoprotein induction and inhibition. AAPS PharmSci Vol. 5, No. 4, Abstract W4372, 2003.
124. Matheny, C, Ali, RY, Yang, X, and Pollack, GM. Effect of prototypical inducers on P-glycoprotein expression in vivo: Tissue specificity and dose-response relationships. AAPS PharmSci Vol. 5, No. 4, Abstract W4373, 2003.
125. Heinzen, EL and Pollack, GM. The role of nitric oxide as a mediator of morphine antinociceptive tolerance. AAPS PharmSci Vol. 5, No. 4, Abstract T3389, 2003.
126. Hoffmaster, KA, Zamek-Gliszczynski, MJ, Pollack, GM, and Brouwer, KLR. P-glycoprotein maintains partial biliary excretion of the opioid peptide [D-pen2,5]enkephalin in multidrug resistance-associated protein (Mrp2)-deficient TR- rat liver. AAPS PharmSci Vol. 5, No. 4, Abstract W4361, 2003.
127. Hoffmaster, KA, Zamek-Gliszczynski, MJ, Pollack, GM, and Brouwer, KLR. Mechanisms of hepatic uptake and biliary excretion of the metabolically stable P-glycoprotein substrate [D-pen2,5]enkephalin. Drug Metab. Rev., 2003.
128. Turncliff, R, Pollack, GM, and Brouwer, KLR. Pharmacokinetics of terfenadine and fexofenadine in sandwich-cultured rat hepatocytes. Drug Metab. Rev., 2003.
129. Mowrey, B and Pollack, GM. A pharmacokinetic/pharmacodynamic analysis of the influence of P-glycoprotein on the pharmacodynamics of the opioid peptide [D-penicillamine2,5]enkephalin. AAPS PharmSci Vol 6, No. 4, 2004.
130. Graff, CL and Pollack, GM. Drug delivery to the brain after intranasal administration: The role of P-glycoprotein. AAPS Journal Vol 6, No. 4, 2004.
131. Kalvass, JC and Pollack, GM. The influence of albumin and microsomal protein concentration on estimates of in vitro kinetic parameters. AAPS Journal Vol 6, No. 4, 2004.
132. Yang, X, Graff, CL, and Pollack, GM. Influence of P-glycoprotein induction on methadone pharmacodynamics. AAPS Journal Vol 6, No. 4, 2004.
133. Zhao, R, Graff, CL, and Pollack, GM. Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation. AAPS Journal Vol 6, No. 4, 2004.
134. Heinzen, EL, Booth, RG, and Pollack, GM. Morphine-induced neuronal nitric oxide production modulates constitutive activity of the mu-opioid receptor to mediate antinociceptive tolerance development. AAPS Journal Vol 6, No. 4, 2004.
135. Kalvass, JC, Olson, ER, and Pollack, GM. Influence of blood-brain barrier P-glycoprotein on brain penetration and antinociceptive effects of model opioids. AAPS Journal Vol 7, No. S2, 2005.
136. Olson, ER, Kalvass, JC, and Pollack, GM. The influence of hotplate latency methodology on measures of antinociception. AAPS Journal Vol 7, No. S2, 2005.
137. Kalvass, JC and Pollack, GM. Prediction of brain extracellular fluid concentrations: application to understanding central nervous system pharmacokinetics and pharmacodynamics. AAPS Journal Vol 8, No. S2, 2006.
138. Olson, ER and Pollack, GM. A novel method for determining the area bounded by a hysteresis loop. AAPS Journal Vol 8, No. S2, 2006.
139. Padowski, JM and Pollack, GM. An in vitro pharmacodynamic model of U251 glioma cell response to paclitaxel. AAPS Journal Vol 8, No. S2, 2006.
140. Zhao, R and Pollack, GM. Enhanced brain penetration of cimetidine after nasal administration to mice. AAPS Journal Vol 8, No. S2, 2006.